Toos Daemen

List of Publications by Year
in descending order

110 papers	6,402 citations	101496 36 h-index	69214 77 g-index
112 all docs	112 docs citations	112 times ranked	9605 citing authors

#	Article	IF	Citations
1	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British Journal of Cancer, 2011, 105, 93-103.	2.9	1,045
2	Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 1995, 17, 31-48.	6.6	788
3	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunology, Immunotherapy, 2009, 58, 449-459.	2.0	347
4	A potential role of macrophage activation in the treatment of cancer. Critical Reviews in Oncology/Hematology, 2002, 44, 143-161.	2.0	291
5	Myeloid derived suppressor cellsâ€"An overview of combat strategies to increase immunotherapy efficacy. OncoImmunology, 2015, 4, e954829.	2.1	219
6	Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Research, 2001, 61, 7305-9.	0.4	146
7	Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. International Journal of Cancer, 1995, 61, 716-721.	2.3	132
8	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. Clinical Cancer Research, 2016, 22, 2342-2350.	3.2	132
9	Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine, 2002, 20, 2287-2295.	1.7	124
10	Immunization with a P53 synthetic long peptide vaccine induces P53â€specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer, 2009, 125, 2104-2113.	2.3	123
11	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	123
12	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. OncoImmunology, 2017, 6, e1338230.	2.1	116
13	Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7. Clinical Cancer Research, 2007, 13, 2385-2391.	3.2	99
14	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. OncoImmunology, 2015, 4, e989764.	2.1	95
15	Virosomes for antigen and DNA delivery. Advanced Drug Delivery Reviews, 2005, 57, 451-463.	6.6	94
16	Potentiation of a p53â€SLP vaccine by cyclophosphamide in ovarian cancer: A singleâ€arm phase II study. International Journal of Cancer, 2012, 131, E670-80.	2.3	81
17	Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clinical and Experimental Immunology, 2007, 150, 199-209.	1.1	76
18	Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs. Bioscience Reports, 2002, 22, 323-338.	1.1	72

#	Article	IF	Citations
19	In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Research, 1986, 46, 4330-5.	0.4	69
20	Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology, 1997, 26, 416-423.	3.6	65
21	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	0.8	64
22	Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine, 2003, 21, 1082-1088.	1.7	63
23	Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Therapy, 2002, 9, 85-94.	2.3	60
24	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6, 32228-32243.	0.8	58
25	Toxicity of doxorubicin entrapped within long-circulating liposomes. Journal of Controlled Release, 1997, 44, 1-9.	4.8	55
26	Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Therapy, 2000, 7, 1859-1866.	2.3	53
27	Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization. Antiviral Therapy, 2004, 9, 733-742.	0.6	53
28	Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses. Journal of Infectious Diseases, 2011, 204, 377-384.	1.9	52
29	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2016, 22, 714-724.	3.2	51
30	Noninvasive monitoring of cancer therapy induced activated T cells using [¹⁸F]FB-IL-2 PET imaging. OncoImmunology, 2017, 6, e1248014.	2.1	51
31	Longâ€term clinical and immunological effects of p53â€SLPÂ® vaccine in patients with ovarian cancer. International Journal of Cancer, 2012, 130, 105-112.	2.3	49
32	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Molecular Therapy, 2021, 29, 611-625.	3.7	48
33	Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. British Journal of Cancer, 2010, 103, 685-692.	2.9	43
34	Influenza Virosomes in Vaccine Development. Methods in Enzymology, 2003, 373, 74-91.	0.4	42
35	Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Therapy, 2005, 12, 1410-1414.	2.3	39
36	Therapeutic immunization and local lowâ€dose tumor irradiation, a reinforcing combination. International Journal of Cancer, 2014, 134, 859-872.	2.3	38

#	Article	IF	Citations
37	Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. OncoImmunology, 2018, 7, e1487913.	2.1	36
38	Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. Invasion & Metastasis, 1993, 13, 102-12.	0.5	36
39	P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. International Journal of Cancer, 2007, 121, 606-614.	2.3	34
40	Modulation of pharmacokinetic behavior of liposomes. Advanced Drug Delivery Reviews, 1997, 24, 179-191.	6.6	33
41	Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecologic Oncology, 2008, 110, 365-373.	0.6	32
42	Immunologic aspect of ovarian cancer and p53 as tumor antigen. Journal of Translational Medicine, 2005, 3, 34.	1.8	31
43	Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. Journal of Clinical Virology, 2006, 35, 233-243.	1.6	31
44	Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	31
45	Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. Vaccine, 2004, 22, 1104-1113.	1.7	30
46	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. British Journal of Cancer, 2014, 110, 1535-1544.	2.9	30
47	Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. Molecular Therapy, 2014, 22, 881-890.	3.7	30
48	Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. Vaccines, 2015, 3, 203-220.	2.1	29
49	Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins. Journal of Controlled Release, 1997, 46, 165-175.	4.8	28
50	Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF. Gene Therapy, 2001, 8, 300-307.	2.3	28
51	Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands. Vaccine, 2009, 27, 4776-4783.	1.7	28
52	Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. OncoImmunology, 2021, 10, 1898753.	2.1	28
53	Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antiviral Therapy, 2004, 9, 733-42.	0.6	28
54	VIROSOMES IN VACCINE DEVELOPMENT: INDUCTION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY WITH VIROSOME-ENCAPSULATED PROTEIN ANTIGENS. Journal of Liposome Research, 2002, 12, 155-163.	1.5	27

#	Article	IF	Citations
55	A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Therapy, 2007, 14, 1695-1704.	2.3	27
56	On Discounting of Health Gains from Human Papillomavirus Vaccination: Effects of Different Approaches. Value in Health, 2012, 15, 562-567.	0.1	27
57	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. OncoImmunology, 2014, 3, e962397.	2.1	27
58	Therapy of Murine Liver Metastases by Administration of MDP Encapsulated in Liposomes. Selective Cancer Therapeutics, 1990, 6, 63-71.	0.5	26
59	Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Research, 2012, 96, 36-50.	1.9	26
60	Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infectious Diseases, 2013, 13, 75.	1.3	26
61	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. Journal of Immunotherapy, 2011, 34, 516-523.	1.2	25
62	A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. OncoImmunology, 2015, 4, e1029699.	2.1	23
63	Tumoricidal response of liver macrophages isolated from rats bearing liver metastases of colon adenocarcinoma. Journal of Leukocyte Biology, 1995, 57, 617-623.	1.5	22
64	Endocytic and Tumoricidal Heterogeneity of Rat Liver Macrophage Populations. Selective Cancer Therapeutics, 1989, 5, 157-167.	0.5	21
65	Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer. Gynecologic Oncology, 2009, 113, 256-263.	0.6	21
66	Proliferation of rat liver macrophagesin vitro: Influence of hemopoietic growth factors. Hepatology, 1994, 19, 666-674.	3.6	20
67	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. British Journal of Cancer, 2015, 113, 786-793.	2.9	20
68	A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease. Antiviral Therapy, 2006, 11, 717-728.	0.6	20
69	Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Therapy, 2008, 15, 393-403.	2.3	19
70	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2014, , CD007287.	1.5	19
71	An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Cancer Immunology, Immunotherapy, 2019, 68, 849-859.	2.0	19
72	Heterologous Prime-Boost Immunizations with a Virosomal and an Alphavirus Replicon Vaccine. Molecular Pharmaceutics, 2011, 8, 65-77.	2.3	18

#	Article	IF	Citations
73	Activation of Kupffer cell tumoricidal activity by immunomodulators encapsulated in liposomes. Research in Immunology, 1992, 143, 211-214.	0.9	17
74	Virosomes as an Antigen Delivery System. Journal of Liposome Research, 2000, 10, 329-338.	1.5	17
75	Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. International Journal of Cancer, 2006, 118, 2529-2537.	2.3	17
76	Heterogeneity in secretory responses of rat liver macrophages of different size. Liver, 1995, 15, 313-319.	0.1	17
77	Equity in human papilloma virus vaccination uptake?: sexual behaviour, knowledge and demographics in a cross-sectional study in (un)vaccinated girls in the Netherlands. BMC Public Health, 2014, 14, 288.	1.2	17
78	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Therapy, 2015, 22, 560-567.	2.3	17
79	Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antiviral Therapy, 2011, 16, 207-218.	0.6	16
80	Costâ€“effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine, 2013, 31, 3922-3927.	1.7	16
81	Hepatitis C virus core or NS3/4A protein expression preconditions hepatocytes against oxidative stress and endoplasmic reticulum stress. Redox Report, 2019, 24, 17-26.	1.4	15
82	The cellular stress response in hepatitis C virus infection: A balancing act to promote viral persistence and host cell survival. Virus Research, 2019, 263, 1-8.	1.1	15
83	T-cell maturation in the human thymus and tonsil: Peanut agglutinin binding T lymphocytes in thymus and tonsil differ in maturation stage. Clinical Immunology and Immunopathology, 1983, 29, 271-281.	2.1	14
84	Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. Vaccines, 2015, 3, 221-238.	2.1	14
85	Vaccine-based clinical trials in ovarian cancer. Expert Review of Vaccines, 2011, 10, 775-784.	2.0	13
86	Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis. Vaccines, 2021, 9, 1166.	2.1	13
87	Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat. Clinical and Experimental Metastasis, 1995, 13, 328-36.	1.7	12
88	Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. Advanced Drug Delivery Reviews, 1995, 17, 21-30.	6.6	12
89	Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen. Current Pharmaceutical Design, 2012, 18, 3804-3811.	0.9	12
90	HPV-Specific Immunotherapy: Key Role for Immunomodulators. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 265-279.	0.9	12

#	Article	IF	Citations
91	Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes. Journal of Immunology, 1989, 142, 2469-74.	0.4	12
92	Liposomes in chemo- and immunotherapy of cancer. Lipids, 1987, 22, 891-896.	0.7	11
93	The costâ€"effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert Review of Vaccines, 2015, 14, 589-604.	2.0	11
94	Antigen-specific active immunotherapy for ovarian cancer. The Cochrane Library, 2018, 9, CD007287.	1.5	11
95	Hepatitis C Virus Proteins Core and NS5A Are Highly Sensitive to Oxidative Stress-Induced Degradation after eIF2Î±/ATF4 Pathway Activation. Viruses, 2020, 12, 425.	1.5	11
96	The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virusâ€related hepatocellular carcinoma. International Journal of Cancer, 2022, 151, 809-824.	2.3	11
97	Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine, 2010, 28, 4275-4282.	1.7	10
98	TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall. Molecular Therapy, 2017, 25, 2289-2298.	3.7	8
99	GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles. European Journal of Pharmaceutical Sciences, 2020, 143, 105096.	1.9	8
100	A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Molecular Therapy - Oncolytics, 2021, 23, 239-253.	2.0	7
101	Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health, 2018, 18, 837.	1.2	6
102	Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. Molecular Imaging and Biology, 2020, 22, 883-890.	1.3	6
103	Therapeutic Vaccines and Cancer Immunotherapy. Vaccines, 2020, 8, 596.	2.1	6
104	Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?. , 2019, 7, 251513551987467.	1.4	2
105	Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. , 0, .		2
106	PCN13 Analysis of the Impact of Prophylactic Vaccination Against Human Papillomavirus Infection Using a Dynamic-Modelling Approach. Value in Health, 2012, 15, A411.	0.1	0
107	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
108	Cost-Effectiveness of Additional Human Papillomavirus Vaccination Programmes, in The Netherlands. Value in Health, 2017, 20, A443.	0.1	0

#	Article	IF	Citations
109	SP-0553 Imaging of tumor infiltrating lymphocytes with [18F]FB-IL2 PET. Radiotherapy and Oncology, 2019, 133, S291.	0.3	0
110	Abstract A108: CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRÎ±Î²+ CD8Î±Î²+ T cells that can be targeted for cancer immunotherapy. , 2016, , .		0